Tofacitinib fails to prevent t cell transfer colitis in mice but ameliorates disease activity

HIGHLIGHTS

SUMMARY

Regarding cytokine expression, percentages of interleukin 17 (IL-17) producing CD4+ T_cells in spleens and mLNs of tofacitinib treated mice were enhanced, while percentages of IFN-γ producing CD4+ T_cells was reduced (Fig 2I-L). Summing up, low dose tofacitinib starting immediately after transfer during the expansion phase of CD4+ T_cells enhances splenic numbers of CD3+ CD4+ T_cells as well as of MDSCs and does not prevent colonic inflammation. Percentages of IFN-γ producing T_cells in spleens and mLNs were reduced in the tofacitinib treated mice (Fig 7A,B), while there was no difference in the . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.